iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 788,000 shares, a growth of 149.8% from the June 30th total of 315,400 shares. Approximately 7.9% of the shares of the company are sold short. Based on an average daily volume of 4,240,000 shares, the days-to-cover ratio is currently 0.2 days.
iSpecimen Stock Performance
Shares of ISPC stock traded up $0.00 during midday trading on Friday, hitting $0.29. 803,595 shares of the company were exchanged, compared to its average volume of 2,309,303. iSpecimen has a 52 week low of $0.20 and a 52 week high of $1.75. The firm has a market capitalization of $3.77 million, a P/E ratio of -0.22 and a beta of 1.60. The firm’s 50 day moving average price is $0.33 and its two-hundred day moving average price is $0.35.
iSpecimen (NASDAQ:ISPC – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter. iSpecimen had a negative return on equity of 105.25% and a negative net margin of 124.84%. The firm had revenue of $2.29 million for the quarter.
About iSpecimen
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
Further Reading
- Five stocks we like better than iSpecimen
- Golden Cross Stocks: Pattern, Examples and Charts
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Compound Interest and Why It Matters When Investing
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.